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Appropriate frameworks for economic evaluation of end of life care: A qualitative 
investigation with stakeholders 
Abstract 
Background: The use of quality-adjusted life years rests on the assertion that the objective of 
the healthcare system is to improve health. 
Aim: To elicit the views of expert stakeholders on the purpose and evaluation of supportive 
end of life care, and explore how different purposes of end of life care imply the need for 
different evaluative frameworks. 
Design: Semi-structured qualitative interviews, analysed through an economic lens using a 
constant comparative approach. 
Participants: .20 professionals working in or visiting the UK or Republic of Ireland, with 
clinical experience and/or working as academics in health-related disciplines. 
Results: Four purposes of end of life care were identified from and are critiqued with the aid 
of the qualitative data: to improve health; to enable patients to die in their preferred place; to 
enable the patient to experience a good death; to enable the patient to experience a good 
death, and those who are close to the patient to have an experience which is as free as 
possible from fear, stress and distress. 
Conclusion: Managing symptoms and reducing anxiety were considered to be core 
objectives of end of life care and fit with the wider health service objective of 
improving/maximising health. A single objective across the entire health system ensures 
consistency in the way that resource allocation is informed across that entire system.  
However, the purpose of care at the end of life is more complex, encompassing diverse and 
patient-centred objectives which we have interpreted as enabling the patient to experience a 
good death. 
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What is already known about the topic? 
 Economic evaluation informs the efficient use of health and care resources.   
 Competing options are typically assessed in terms of their costs and their impact, in 
terms of quality adjusted life years (health gain and life extension). 
What this paper adds: 
 We use qualitative accounts from expert stakeholders to explore the purpose of 
supportive end of life care, starting from the position that the criteria for evaluating 
supportive end of life care should match its purpose. 
Implications for practice, theory or policy 
  The views of stakeholders in terms of what supportive end of life care should ‘ideally’ 
be trying to achieve broadly equates to ensuring the ability to experience a good death. 
 At best, quality adjusted life years and the policy agenda around place of death crudely 
relate to such an objective and hence an alternative evaluative framework should be 
explored.    
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1. Introduction 
Scarcity is openly acknowledged in strategy and review documents relating to supportive end 
of life care (1, 2).  Economists have an important role to play in providing evidence on the 
cost-effectiveness of health and social care interventions, to inform decision-makers and 
commissioners.  However, as the MORECare statement (3) –which promotes consensus on 
methods for end of life care research– indicated, there are ‘strongly opposing’ views about 
the use of quality adjusted life years (QALYs) in the end of life care context.  This lack of 
consensus is apparent from the relatively small literature in this area (4-8). 
‘Reference cases’ are set for economic evaluation by regulatory bodies to facilitate 
comparison of cost-effectiveness results across a diverse set of competing healthcare 
interventions/services.  The reference cases of regulatory bodies such as the National Institute 
for Health and Care Excellence (NICE) in the UK (9) and the ZorgInstituut Nederlands in the 
Netherlands (10) specify that QALYs should be calculated based upon an assessment of 
health functioning.  Tariff values combine information from the five items of EQ-5D into a 
single score, reflecting societal preferences (11), which is then used to calculate QALYs. 
Two alternative means of promoting efficiency across diverse sets of healthcare services are 
the use of cost-benefit analysis (the valuation of outcomes in monetary terms) and the use of 
generic measures of well-being within cost-effectiveness analysis.  For social care, the NICE 
reference case provides for the use of broad well-being measures such as ASCOT and 
ICECAP (12).  Tariff values are available to summarise states defined by ASCOT (13) and 
ICECAP measures (14, 15). 
With any generic measure/framework, sensitivity may be compromised in order to facilitate 
comparability.  Normand notes that the QALY is insensitive to the complex and 
multidimensional objectives of palliative care and that, because there is limited scope for 
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QALY gains, the QALY framework will tend towards bias against palliative care 
interventions (6).  Palliative care interventions may not, therefore, be cost-effective, despite 
being valued by society; a phenomenon which has been dubbed the “QALY problem” (6), 
although the same issue could apply to any generic evaluative space which is insensitive to 
end of life care outcomes. 
Normand suggests that the appropriate solution to the “QALY problem” depends upon 
whether the need is to make comparisons between end of life care and other forms of health 
and social care or to make optimal use of end of life care resources (6).  In the latter case, 
cost-effectiveness analysis (where there is a single, natural unit of outcome) will be adequate.  
There are a wide range of outcomes which could be selected as the (single) focus of cost-
effectiveness analysis, such as pain score, place of death, or the patient’s broader wishes 
being recorded and realised. 
Finally, work has been undertaken by health economists within recent years to develop 
context specific measures for evaluating supportive end of life care, one example of which is 
the ICECAP-SCM (Supportive Care Measure) (16).  Such measures potentially offer greater 
sophistication than reliance on a single policy variable.  A choice of evaluative space, aligned 
to any of the frameworks introduced here is as much of a choice as to what to exclude from 
analysis as it is about what it is that should be included. 
The starting point for the study outlined in this paper is that, in determining the framework 
for economic evaluation in the end of life context, the purpose of end of life care should first 
be established.  Otherwise, economic evaluation risks perversely and adversely influencing 
resource allocation.   
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2. Methods 
This research utilised a qualitative approach to understanding the perceptions of expert 
stakeholders on the purpose of end of life care, adopting a subtle realist philosophical 
perspective (17) and analysing data through an economic lens (18).  Qualitative interviews 
were conducted with academic stakeholders with expertise relevant to the topic of economic 
evaluation and end of life care.  Ethical approval for the research was obtained from the 
Science, Technology, Engineering and Mathematics Ethical Review Committee at the 
University of Birmingham [ERN_11-1293]. 
2.1 Sample & Recruitment 
Sampling aimed to draw on a wide variety of perspectives in a form of maximum variation 
sampling (19), with variation across and within (clinical and non-clinical) academic 
disciplines, as reported elsewhere (20).  It was anticipated that a sample size of around 20 
would be sufficient to capture the main perspectives. 
Stakeholders currently working in, or visiting, the UK or Republic of Ireland were identified 
through: searches of conference programmes and public websites of key research institutions; 
known contacts of the research team and advisory group; publicly listed membership of 
NICE Technology Appraisal Committees; snowball sampling.  Stakeholders were invited via 
email; with one email reminder if appropriate.  An information leaflet detailed the aims of the 
study, together with funding and the methods to be used for data collection. 
2.2 Data Collection 
Semi-structured one-to-one interviews were conducted during 2012/3 by PK.  Interviews 
lasted between 45 and 80 minutes and were audio-recorded.  A topic guide was followed, 
including: participant’s background and experience; purpose and current provision of care at 
the end of life; context for economic evaluation at end of life; general outcomes of 
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importance; economic outcomes; timing and defining the ‘end of life period’; assessment of 
outcomes.  Appendix A contains the topic guide and further detail relating to data collection. 
2.3 Analysis 
Audio recordings were transcribed verbatim.  Transcripts were analysed in batches of 
between three and six, using constant comparison and the writing of analytic accounts.  
Transcripts were coded by both authors, themes were identified inductively, drawing on the 
economic disciplinary ‘mode of thinking’ of both authors (21), and were refined and 
modified as analysis progressed and analytic accounts were formed, compared and refined 
(22).   
In the quotations reported, participants are identified by study number and discipline: Health 
Economics (HE); Nursing and Allied Health (NA); Health Psychology (HP); Physician (DR); 
Philosophy/Ethics (PE).   
3. Results 
Thirty three individuals were invited to participate; 20 interviews were conducted.  
Participants were: HE (n=6); NA (n=6); HP (n=3); DR (n=3); PE (n=2).  Characteristics of 
participants are reported in Table 1. 
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Table 1: Characteristics of Participants: 
Participant Background/Experience Number of Participants 
Institutional Affiliation 
Academic 
NHS with honorary academic contract 
Non-University Research-focused Organisation 
 
16 
3 
1 
Academic/Clinical Discipline 
Ethics/Philosophy 
Health Economics 
Health Psychology 
Medical Doctor 
Nursing/Allied Health 
 
2 
6 
3 
3 
6 
Direct Clinical Experience/Healthcare Delivery 
Yes 
No 
 
8 
12 
 
 
3.1 Summary of the themes arising 
Ten initial themes emerged and reflect the full breadth of the qualitative data.  These themes 
and a diagrammatical representation of the interaction between them is summarised in Figure 
one.  Where there is significant interaction between themes, these have been grouped together 
within a dotted outline (for example, it was sometimes artificial to distinguish between 
outcomes for the patient and outcomes for the family). 
[Insert figure 1 here] 
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Information revealing participants’ views on the purpose of end of life care crossed through 
each of the ten initial themes.  Possible contradictions could be identified across interviews, 
for example some who were critical of place of death as an outcome had used this outcome in 
their own research, and two participants in particular who advocated the use of QALYs 
nevertheless listed non-health outcomes they envisaged would be important to patients.  
Complex concepts were sometimes expressed through recalling experiences (stories).  Four 
purposes of end of life care were identified: 
1. To improve (or maximise) the health of patients.   
2. To enable patients to die in their preferred place. 
3. To enable patients to experience a good death. 
4. Positions one, two or three with the inclusion of the impact upon family and informal 
carers. 
3.2 Health Gain 
Most participants referred to controlling/relieving symptoms (most frequently pain) as a key 
element of end of life care.  However, there was also explicit acknowledgement by many that 
end of life care is unlikely to significantly improve health, and thus some suggested that to 
assess end of life care in terms of health improvement was to set services up to fail: 
In palliative care your input is an ill patient and your output is a dead patient 
(13NA) 
…we know a number of things: one is, by the very nature of it, the person’s going to 
die; so if you’re saying what’s their health status at six months or whenever? Dead.  
... so if you’re using as an outcome measure how sick they are, all of our studies are 
going to, as it were, fail... (04HP) 
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Others expressed varying degrees of concern about the relevance and sensitivity of particular 
health-related quality of life instruments in the end of life context. Participants also focused 
on process elements such as the importance of communication with patients and family and 
broader support.  These were seen as clearly distinct from health gain and thus not measured 
under this approach. 
Instruments such as EQ-5D or even SF-36 are not adequate... palliative care 
interventions tend to be complex … they’re trying to affect a whole range of things 
from ... physical symptoms to trying to provide a broader support to the individual, 
family and friends...  (09HE) 
I don’t think that health-related quality of life is necessarily the right generic measure.  
It’s not broad enough. (02HE) 
One view here was that the weaknesses associated with the QALY are, far from being 
specific to end of life care, merely more apparent in this context. 
…the issues that arise when you’re trying to develop evidence in palliative care are 
actually very generic ones …it’s just rather more stark… (09HE) 
They’re [QALYs] a useful tool but they clearly aren’t useful in all areas of medicine 
and palliative care is perhaps the clearest example of when they’re not useful. (17PE) 
There were also differing views about the appropriateness of combining health status and 
survival within the QALY.   
I don’t think QALYs are right because that’s looking at survival (01HP) 
... as far as I’m aware, every attempt to come up with a practical alternative to the 
QALY –with respect to trade-offs with time– ... have never really reached success... 
[the QALY] is a pragmatic tool, I’m not aware of any areas, decisions by say NICE, 
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where the nature of those trade-offs between time and quality have clearly generated 
results which are perverse... (12HE) 
Two arguments emerged in favour of assessing the consequences of interventions at the end 
of life in terms of health gain.  First, if health gain is the legitimate objective of the health 
system and if care at the end of life is provided by the health system, then health gain, by 
default, becomes the objective of end of life care.  From the normative viewpoint that health 
alone is of importance as the output of the health system (epitomised by 12HE), it would be 
inappropriate to factor wider impacts into economic evaluation; they would, instead, be seen 
as being either “derived from health” (12HE) or irrelevant. 
I’m not clear whether health systems SHOULD, from a normative perspective, be 
trading those types of broader benefits with other people’s health... (12HE) 
Many participants acknowledged the need for comparability in terms of the results of 
economic evaluation: 
…there’s... lots of debate about how appropriate QALYs are for end of life care… 
I’m quite critical of QALYs [but] I still think that commissioners need some metric 
like that. (07HE) 
Indeed, some felt that comparability was sufficient reason to settle for health gain/QALYs: 
…if you’re to argue for funding against other healthcare activities...it’s perfectly 
reasonable to demonstrate the benefit only in terms of health care… (20DR) 
Hence, whilst there was a divergence of views between those who regarded health gain as the 
sole and legitimate objective of the health system and those advocating a broader focus, there 
was significant agreement that the opportunity cost of investing resources in end of life care 
must (somehow) be compared to the opportunity cost of investing across the rest of the health 
sector.  If health gain can be considered to be a legitimate objective of end of life care, this 
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definition of benefit/outcome clearly facilitates such comparison.  The question that exercised 
informants was just how ‘poor a fit’, in terms of the relevance and realistic opportunity for 
health gain in the case of end of life care, can be tolerated to achieve consistency and 
comparability.   
Factors differentiating care at the end of life included the overlap with social care, the 
inevitable worsening health of the patient, and the shift away from curative intent.  For some 
informants, this meant that the purpose and objectives of end of life care simply do not fit the 
mould that is standard for health economic evaluation. 
 
3.3 Preferred place of death 
The environment in which death occurs is one ‘process’ element that many participants 
considered important and policy relevant.  Participants discussed particular characteristics of 
preferred place of death.  They used ‘comfortable’ and ‘safe’ as positive terms when referring 
to the care environment, and ‘fear’ and ‘distress’ as negative terms. 
there’s ...an aversion for people to ...be in a high intensity environment, where it’s 
noisy, the lights are bright, they’re in an over-crowded situation with strangers, 
compared to somewhere where it’s ...peaceful, comfortable… and you’re with the 
people you want to be there with... (19HE) 
supporting the process of dying in a way that enables the patient to have a death 
which is … in a place... that doesn't add stress and harm (13NA) 
Dying in acute care was generally seen as a poor outcome, with dying at home or in a hospice 
seen as positive.  In part this seemed to relate to the lack of opportunity in an acute 
environment to develop trusting relationships with staff and for staff to understand patients’ 
wishes: 
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In the acute environment … [care] is very poor, it’s marginalised, it’s frightening to 
everybody concerned. (11NA) 
Patients often arrive on their own… very often patients aren’t able to communicate… 
information’s lacking, time is of the essence … it’s not until there’s the time and the 
information that you sometimes realise that this isn’t what they wanted (10NA) 
Some participants, however, expressed scepticism about research suggesting a common 
preference for dying at home, and a number expressed the view that patient preferences 
change over the course of the dying trajectory as their condition progresses.  Participants 
frequently acknowledged that the reality of dying at home may be very different from the 
expectation, and that setting unrealistic expectations seems “cruel” (3NA): 
… they’re people who are answering a hypothetical question …  So far away from 
death people choose home and they’re really unrealistic... (06DR) 
 [the acute setting is] an open door…patients know they can get help there …even 
when they have community services, they still chose emergency departments to get 
help and support (10NA) 
There was also concern that a sole focus on place of death could have unwanted 
consequences for others in the family, both in providing unpaid care and broader impacts 
on family life. 
… if home needs adapting, that affects the entire household... (13NA) 
Despite the simplicity of preferred place of death as an outcome, and its use by policy- 
makers, there was little support for its use as an outcome in economic evaluation.  Rather, 
what appeared to be important was to acknowledge heterogeneity between patients and to 
enable each individual patient to experience as good a death as possible.  Place of death 
appears, at best, to be a crude proxy for this more complex aspiration. 
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The purpose is different for everybody you look after ... when it comes to end of life 
care, you don’t know what a patient wants and so you have to negotiate with them 
(06DR) 
 
3.4 “A good death”  
Some participants explored alternatives to the QALY, which involve broadening the 
evaluative space but seeking to maintain some means of comparability.  A relatively small 
number of non-health outcomes were mentioned by participants, including social 
isolation/engagement, spirituality and meaning-making, dignity and respect, putting affairs in 
order, good communication with staff, the environment, and some concept of 
achievement/closure.   
…a more general characterisation of quality of life would include for example their 
ability to be with family, their ability to put their financial affairs straight... do those 
last ...things that they want to do before they ‘shuffle off’ (12HE) 
I would hope that people had done what they wanted to do... those tasks that people 
feel they wish to accomplish (05NA) 
Indeed, when participants gave examples of effective care at the end of life it was often in a 
context in which staff had time and experience, and care was the focus rather than health 
gain. 
…crucial conversations happen when someone’s lying awake at two o’clock in the 
morning and the nurse happens to go in to do the observations (11NA) 
One participant referred to evidence that patients are (or at least indicate that they are) willing 
to trade-off health in order to achieve better quality of life generally, suggesting that a 
broader outcome is feasible: 
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Patients – caregivers to a lesser extent – were still [in Discrete Choice Experiments] 
willing to trade months of survival for those... non health-related benefits... (19HE) 
In terms of consistency, there was some suggestion that additional items could be added 
around a core outcome set, depending upon the condition being studied.  For end of life care, 
those additional outcomes could be thought of as assessing factors which enable ‘a good 
death’ such as communication, environment, having those people around who are important 
to you, spiritual support and a sense of closure/accomplishment: 
I think there has to be a core set of outcomes to inform the decision making process 
but then arguably for any clinical area you might want to have separate measures that 
are specific to that area (07HE) 
A more radical suggestion was that different outcomes be used in different contexts and that a 
more sophisticated means of comparison be established (an “exchange rate”).  
...if we’re serious about being able to support resource allocation, one of the 
objectives has to be comparability between palliative and curative intent ...rather than 
saying let’s have a single measure that you apply across all settings, you have a 
system of validated comparison between measures in different settings... rather like the 
pound-dollar-euro rates, we don’t have a single currency... but we do at any given 
time know how to interpret one currency in terms of another.  (09HE) 
A third alternative was to maintain a consistent, universal measure but ensure that it is 
sufficiently broad. 
...I strongly believe that the framework upon which we base economic evaluation, 
currently, can be applied to anything, but the detail is inadequate... Particularly since 
the development of NICE, there’s a serious lack of flexibility... health economists have 
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just walked away from the theoretical underpinnings of what they do… just kind of 
dumped utility … for a very narrow measure of health-related quality of life… (02HE) 
As well as a broadening of outcomes, it was suggested by one participant that time might be 
considered in terms of the “nature of the trajectory”, rather than “counting the days”. In other 
words, outcomes could be related to an entire experience and not sequences of time; a good 
death or a satisfactory death could perhaps be such an outcome.   
People’s view of the quality of an experience is not simply related to how long it lasts, 
indeed in some cases people would describe as a better experience something that is 
shorter in duration...  it’s not that it [time] is irrelevant, it’s just that it can’t be added 
up like that...  (09HE) 
A number of options were therefore suggested by informants for taking account of the 
different outcomes that are seen as important in relation to a good death.  Inevitably, this 
would make evaluation more complex but could avoid the problem identified by one 
participant that “we often make the things which are least meaningful measurable” (05NA). 
If a different framework is to be used for evaluation of end of life care, however, there are 
difficult questions about when a person would move onto the new framework.  This issue was 
discussed with participants although they found it challenging.  Suggestions from participants 
included: a prognosis of less than a year and an awareness of that prognosis; the first point at 
which the health system engages with a person on the fact that they will soon be dying; the 
point at which it is known that the disease is terminal; the point at which the Liverpool Care 
Pathway would have been initiated (the last few days of life); when people come to realise 
themselves that they are approaching end of life; the point at which palliation becomes the 
treatment priority.  Uncertainty around the trajectory was stressed by most health 
professionals.   
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3. 5 “A good death” with a broad perspective 
Some participants additionally strongly favoured incorporating outcomes for family and 
others close to the patient and indeed some explicitly referred to support for the family when 
summarising the purpose of end of life care. 
...providing end of life care isn’t just to the person, it’s important to provide care to 
their family as well… (06DR)  
Participants tended to think about those close to the patient in two ways, as informal care 
providers who should be supported in caring for the patient and as people who are 
emotionally involved and bear a lasting memory. 
…whether the carer felt well supported, because I think that’s indivisible from outcomes, 
that IS an end of life care outcome actually cos you see the patient and family as an 
indivisible unit (08NA) 
…it can be so difficult, you know, dying in an ambulance or in a hospital, or in A&E, and 
that lives with those families for many, many years (16HP) 
There was, however, concern expressed about the need to integrate properly any inclusion of 
non-patient outcomes into the economic analysis.    
... what’s fundamentally important about any broadening of the perspective on benefits 
and dis-benefits is that we deal with them symmetrically in terms of evaluating new 
technologies, but also on the opportunity cost side  (12HE) 
... And if you did it for end of life care, would you have to do it for all types of care?  
And that could end up putting a lot of burden on analysts...  (18HE) 
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Whilst from a health economics perspective the inclusion of family and persons close to the 
patient is a normative question, from a care perspective, it may be somewhat artificial to 
differentiate between support for the patient and support for those closest to the patient. 
 
4. Discussion 
4.1 Main findings 
Participants confirmed that there are elements of the common (health economics) 
conceptualisation of health that are relevant and important in the end of life context, namely 
pain, discomfort and anxiety.  However, attributes relating to the planning and delivery of 
care, as well as broader factors more personal to the patient, were also identified as important, 
indicating there may be a case for altering the evaluative space typically adopted within 
economic evaluation.   
In the economics literature, those favouring the QALY framework stress that it is intended to 
incorporate information (in addition to utility) relating to the characteristics of people (7); the 
fact that some important (non-health) characteristics of people “such as spirituality or 
preparedness for death” [7 p523] are not included within current instruments (such as EQ-
5D) does not mean they couldn’t be included.  This argument is weakened, however, if the 
rejection of broader outcomes relates to the view, expressed by some participants here, that 
the legitimate objective of the health system is solely to improve health, as well as fear of the 
resulting lack of transparency in terms of displacement (23).     
   
Single proxy outcomes such as preferred place of death could be used in cost-effectiveness 
analysis and, in particular, participants noted the importance given to place of death within 
the policy literature.  However, preferred place of death represents a narrow element of the 
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overall picture: a person could die at home as their preferred place of death, yet also die in 
great pain.  Many strategy and policy documents do refer to dying at home, drawing upon evidence 
that suggests many people (56%-65% in the UK, 74% in the Republic of Ireland) have a prior 
preference to die at home (1, 24).  Dying at home, or more generally in a preferred place, is often seen 
as one, or even ‘the’, important outcome of end of life care in non-economic analysis (25, 26).  
However, current research indicating a common preference for dying at home fails to 
quantify the associated trade-offs, and was generally regarded as unreliable by participants.  
A more nuanced outcome which could be used in cost-effectiveness analysis, which has been 
explored in the published literature (27) is that patients’ preferences are known and adhered 
to. 
Several participants suggested ways of ensuring some degree of consistency/transparency 
across the healthcare system as a whole, whilst facilitating a broader (or alternative) outcome 
space. One solution is to expand the current QALY, i.e. expand the scope of the current 
QALY, but still have one standardised framework.  Perhaps a more appropriate suggestion is 
to add additional end of life care outcomes around the core/generic outcome space (as a 
context-specific bolt-on).  Expanding the QALY framework does not, however, overcome 
issues associated with time and survival.   
A more radical solution involves a stand-alone metric for evaluation in the context of end of 
life care, which conceptualises a ‘good death’.  This position supports recent suggestions for 
using the Capability Approach as a framework for the economic evaluation of end of life 
care, possibly utilising a new capability-based supportive care measure, the ICECAP-SCM 
(4, 28).  Capability is a concept associated with the work of Amartya Sen and Martha 
Nussbaum (29-31). Sen advocates defining well-being with respect to the ability or freedom 
that a person has to achieve the things that they have reason to value. 
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Although the ICECAP-SCM was developed through qualitative work with those approaching 
the end of life, it still involves assessing outcomes using a standardised set of questions.  
Hence whilst it is at least context-specific, there is limited scope for such a measure to 
promote truly patient-centred outcomes and some exchange-rate type mechanism would still 
need to be developed if end of life care services are to be compared with more general health 
services. 
4.2 Strengths and Limitations 
This work has strengths and limitations.  A clear strength is the focus on an under-researched 
area.  Because of the desire to generate a broad understanding of the area from a number of 
perspectives, the number of ‘voices’ in any one disciplinary area is limited.  Nevertheless, 
drawing on the perspectives of clinically qualified academics, psychologists and 
philosophers, in addition to economists, ensured that the analysis was grounded in end of life 
care, as well as conceptual frameworks for economic analysis.  Although the work was 
largely limited to the UK, policy statements internationally state similar priorities for end of 
life care and a minority of participants brought an international perspective. 
4.3 Implications 
The diversity of views about the conduct of economic evaluation of end of life care and the 
clear need for further research for almost all frameworks, suggests that a major implication 
arising from this work is that more research resource is required to generate a greater 
evidence base in this area.  One factor that was identified as important was the need to assess 
the impact of care on those close to the person at end of life and work has recently been 
undertaken to explore this issue (32). 
Many health economists regard the maximisation of health gain as the system-level objective 
of the National Health Service, but if what participants in this study who are healthcare 
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professionals reported trying to achieve for patients and families, and what the wider sample 
listed as being important to patients and family members is interpreted as the objective of end 
of life care, that objective broadly aligns to what we have termed ‘a good death’.  
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